ClinicalTrials.gg

Program

Forazapadin

Its studies are mostly in Muscular Dystrophy, Facioscapulohumeral, led by Satellos Bioscience.

Furthest: phase 2, since Sep 22, 20261 company-led study, 1 open or runningNext primary completion: Dec 30, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Satellos Bioscience11 open or runningphase 2since Sep 22, 2026Sep 22, 2026Dec 30, 2028phase 2 · NCT07872306

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 22, 2026First study: phase 2 study in Muscular Dystrophy, FacioscapulohumeralFirst studyNCT07872306 · 51 planned

Ahead

  1. Dec 30, 2028Primary completion: phase 2 study in Muscular Dystrophy, FacioscapulohumeralNCT07872306

TargetBeta

AAK1 →read by rule
“Forazapadin (SAT 3247) is a potent, orally available, muscle penetrant, small molecule inhibitor of AAK1”study text, by rule · the study

Other programs on AAK1

ProgramCompanyFurthest phaseStudies
SAT-3247ruleSatellos Biosciencephase 23

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07872306Muscular Dystrophy, Facioscapulohumeral2Not yet recruitingDec 30, 202851

How it is read

Names in the registry

  • “forazapadin”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.